DJ-1/PARK7 (human, recombinant)

Confirm delete?

Zoom

Cat No: 23589

Proteins - More Proteins

DJ-1/Parkinson disease protein 7 (PARK7) is a dimeric protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues in oxidatively damaged proteins.{37402} It acts on early glycation intermediates (hemithio...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

HELS67p GATD-2 Nrf-2 p-53 d-GTP PARK-7 SHSY5Y Oncogene DJ1 Epididymis Secretory Sperm Binding Protein Li 67p Parkinsonism-Associated EC 3.5.1.124 3.1.2- EC3.1.2- EC3.5.1.124 HEL-S-67p GATD2 anti-oxidant NQO-1 PINK-1

Product Overview:
DJ-1/Parkinson disease protein 7 (PARK7) is a dimeric protein deglycase that repairs methylglyoxal- and glyoxal-glycated cysteine, arginine, and lysine residues in oxidatively damaged proteins.{37402} It acts on early glycation intermediates (hemithioacetals and aminocarbinols) to prevent the formation of irreversibly damaged advanced glycation end products (AGEs). PARK7 also repairs methylglyoxal- and glyoxal-glycated dGTP, GTP, GDP, GMP, RNA, and DNA.{35071} Knockdown of PARK7 in vitro increases glycated DNA, DNA strand breaks, and phosphorylated p53 levels but decreases mRNA expression of the antioxidant-related enzyme NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1) and destabilizes the nuclear factor erythroid 2-related factor (Nrf2), a master regulator of antioxidant transcriptional responses.{37406} . PARK7 is also a glyoxalase that converts glyoxal and methylglyoxal to glycolic and lactic acid, respectively, in the absence of glutathione.{37403} It acts as a redox-sensitive molecular chaperone and inhibits aggregation of α-synuclein in cell-free assays and in murine neuroblastoma cells.{37404} PARK7 forms a complex with the E3 ubiquitin ligase Parkin and PTEN-induced putative kinase 1 (PINK1) that promotes ubiquitination and degradation of Parkin substrates, including Parkin itself and Synphilin-1 in neuroblastoma SH-SY5Y cells and human brain lysates.{37405} Mutations to PARK7 have been linked to autosomal recessive, early-onset Parkinson’s disease.{37407}

Size	100 µg
Shipping	dry ice
Formulation	50 mM HEPES, pH 8.0, 150 mM sodium chloride, and 10% glycerol
Purity	≥90% estimated by SDS-PAGE
Custom Code	3504.00
UNSPSC code	12352204

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.